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without known treatment poses questions that challenge the
sacrosanct recommendation for randomized controlled trials.
When a disease has a mortality rate close to 40% (as for the
ongoing Ebola outbreak) and when a potential treatment exists,
is it reasonable to design a preliminary simple and brief study to
observe a decrease of mortality rate of 50%, needing to include
only 40 individuals, compared with a retrospective study. This
query emerged a few years ago, but recommendations sup-
ported blindly by evidence-based medicine have become the
rule. Recommendations considered to be the best are those
that are based on at least two double-blind randomized studies
performed by two independent scientiﬁc teams. This was
particularly used in oncology and cardiovascular diseases,
where studies can easily include a large number of patients with
stereotypical clinical involvement. The application of such
studies in infectious diseases remains hazardous.
First, it is very complex to randomize infected patients from
different countries for several clinical syndromes such as
meningitis or pneumonia. Indeed, infectious diseases are
frequently associated with speciﬁc ecosystems and conse-
quently the treatments that seem suitable in some parts of the
world are not effective in other regions. As an example—the
main cause of blood-culture-negative endocarditis after surgery
in western countries, as investigated using molecular tools, is
Streptococcus spp. whereas in Thailand a zoonotic causative
bacterium is usually involved (Coxiella burnetii, Bartonella spp.,
Streptococcus suis) [1,2]. Consequently, the results from ran-
domized controlled trials performed in western countries
could not be effectively applied in southern countries. Indeed,
the epidemiology of infectious disease resists globalization.Clinical Microbiology and Infection © 2015 European Society of CRegarding deadly diseases, the problem of evaluating Ebola
therapies was comprehensively illustrated by the parachute
paradigm, published in 2003 in the British Medical Journal. The
authors performed a meta-analysis on the use of a parachute
after gravitational challenge and observed, not surprisingly, that
no randomized controlled trials of parachute use had been
published [3]! Consequently, the authors proposed that those
individuals who insist that all interventions need to be validated
by a double-blind randomized controlled trial be included in a
study where they are equipped with a bag with or without
parachute and undergo a gravitational challenge. Strangely, it
seems that the authors have failed to include enough volunteers!
In addition, what would be the opinion of an ethics committee?
Recently, part of the science community, mainly composed
of the more rigorous methodologists, denounced that ran-
domized controlled trials of Ebola management had not been
proposed to seriously evaluate therapeutic management [4]. In
parallel, we observed that all the healthcare workers from
western countries infected with Ebola had received, after
repatriation, the best available supporting care plus all the
available experimental treatments but were never evaluated.
Would it be ethical to oppose for western healthcare workers
a strategy based on “any medical solution to avoid death”,
while for African individuals we would propose randomized
clinical trials? In deadly clinical situations, we should forget
methodology to return to previous practices, that of the tyr-
anny of the evidence. Compassionate treatment should be
largely proposed in such a situation. In addition, the expert
opinions of the clinicians who have managed several tens or
hundreds of patients, in contrast to those of specialists in
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